Explore Currently Enrolling Genentech and Roche Clinical Trials in Oncology

Search for clinical trials by making selections below.

Tumor Type View All

Breast Gastrointestinal Genitourinary Gynecologic Hematology Lung Melanoma Solid Tumor

Phase

III II I

Molecule*

Select...
Antibody-drug conjugate (RG7986) Anti-MUC16 TDC (RG7882) Anti-TIGIT MAb (MTIG7192A, RG6058) Atezolizumab (anti-PDL1 MAb) (RG7446) BET inhibitor (TEN-010, RG6146) CD20 TCB (RG6026) CD20 TDB (RG7828) CEA TCB (RG7802) Cergutuzumab amunaleukin (CEA-IL2v) (RG7813) ChK1 inhibitor (GDC-0575, RG7741) Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) Codrituzumab (anti–glypican-3 MAb) (GC33, RG7686) Emactuzumab (anti–CSF-1R MAb) (RG7155) FAP-DR5 biMAb (RG7386) FAP-IL2v FP (RG7461) Glypican-3/CD3 biMAb (CHU) Idasanutlin (MDM2 antagonist) (RG7388) Ipatasertib (Akt inhibitor) (GDC-0068, RG7440) Monoclonal antibody (RG6160) Obinutuzumab Pan-RAF inhibitor (RG6185) Personalized cancer vaccine (RG6180) PI3K inhibitor (GDC-0077, RG6114) Polatuzumab vedotin (anti-CD79b ADC) (RG7596) Raf/MEK dual inh Selective estrogen receptor degrader (SERD[2]) (GDC-0927/SRN-927, RG6047) Selicrelumab (anti-CD40 MAb) (RG7876) Taselisib (PI3K inhibitor) (GDC-0032, RG7604) Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) Venetoclax (BCL-2 inhibitor) (ABT-199/GDC-0199, RG7601)

US Region

International

Region

Select...
Clear All
View Results
Expand +

Tumor Type: Solid Tumor

Phase: PHASE I

Region:

Molecule:

For more information about recruiting clinical trials, please call the Trial Information Support Line for US Clinical Trial information at 888-662-6728 or visit ClinicalTrials.gov.
Email your search results to yourself.
Clear All
View Results
Tumor Type Phase Molecule* Location Study Contact
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AR NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AR
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AZ NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) AZ
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) CA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) DE NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) DE
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) ES NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) ES
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FL NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FL
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FR NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) FR
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) GB NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) GB
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IL NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IL
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IT NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) IT
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) MA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) MA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) NY NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) NY
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) PA NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) PA
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TX NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Solid Tumor II, I Cobimetinib (MEK inhibitor) (GDC-0973, RG7421) TX
NCT02639546—Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AU NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) AU
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CO NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CO
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CT NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) CT
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) ES NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) ES
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) FR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) FR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) KR NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) KR
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MA NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MA
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MD NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) MD
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) NY NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) NY
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) TN NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Solid Tumor I Anti-TIGIT MAb (MTIG7192A, RG6058), Atezolizumab (anti-PDL1 MAb) (RG7446) TN
NCT02794571—Safety and Pharmacokinetics (PK) of Escalating Doses of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) BE NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) BE
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) CT NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) CT
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) ES NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) ES
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) FR NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) FR
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) MA NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) MA
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) NY NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Emactuzumab (anti–CSF-1R MAb) (RG7155) NY
NCT02323191—A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) AZ NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) AZ
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CA
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CO
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) CT
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NV
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NY NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) NY
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Personalized cancer vaccine (RG6180) TN
NCT03289962—A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) CA NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) CA
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) DK NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) DK
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) ES NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) ES
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) FR NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) FR
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) NL NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Selicrelumab (anti-CD40 MAb) (RG7876) NL
NCT02304393—A Study of RO7009789 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) BE NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) BE
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) FR NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Solid Tumor I Atezolizumab (anti-PDL1 MAb) (RG7446), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) FR
NCT01688206—A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CA NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CA
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CA NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CA
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CO NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CO
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CT NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab CT
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab DK NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab DK
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab ES NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab ES
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab IT NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab IT
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab MA NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab MA
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab NL NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab NL
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab NY NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab NY
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab SC NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab SC
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I CEA TCB (RG7802), Obinutuzumab TN NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Solid Tumor I CEA TCB (RG7802), Obinutuzumab TN
NCT02324257—A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) BE NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) BE
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) FR NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) FR
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) NY NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) NY
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) PA NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Solid Tumor I Emactuzumab (anti–CSF-1R MAb) (RG7155), Selicrelumab (anti-CD40 MAb) (RG7876) PA
NCT02760797—A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) CA NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) CA
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) ES NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) ES
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) FR NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) FR
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) GB NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) GB
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) MA NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) MA
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) NY NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) NY
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) TN NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Solid Tumor I PI3K inhibitor (GDC-0077, RG6114) TN
NCT03006172—To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) CA NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) CA
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) DK NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) DK
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Solid Tumor I Selicrelumab (anti-CD40 MAb) (RG7876), Vanucizumab (anti–ANG2-VEGF biMAb) (RG7221) ES
NCT02665416—Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of RO7009789 With Vanucizumab in Metastatic Solid Tumors
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) AZ
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) CA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) ES
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) FL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) IL
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MA
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) MO
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) NY
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) OK
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TN
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Tumor
Type
Phase Molecule* Location
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Solid Tumor I Taselisib (PI3K inhibitor) (GDC-0032, RG7604) TX
NCT01296555—A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
1 of 87 clinical trials
1-4 of 87 clinical trials
ClickTap on the NCT numbers above to visit ClinicalTrials.gov for further details about each trial, including eligibility criteria, primary and secondary outcome measures, and contacts and locations.
This website is intended for US healthcare professionals and contains information on investigational compounds and drug uses that have not been approved by the FDA. Click "OK" if you are a healthcare professional and wish to proceed.
CancelOK
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech. Genentech makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.
CancelContinue
The list of international studies is not comprehensive; only international studies that also include actively enrolling US sites are listed.

Click "OK" if you wish to proceed.
CancelOK